Skip to main content

Enanta Pharmaceuticals, Inc.

corporate_fare Company Profile

Enanta Pharmaceuticals, Inc.

ENTA·NASDAQ·Life Sciences·CIK 0001177648

Enanta Pharmaceuticals, Inc. is a biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs, with an emphasis on viral infections and immunological diseases. In virology, Enanta discovered glecaprevir, the second of two antiviral protease inhibitors developed through its collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's leading brand of direct-acting antiviral (DAA) combination treatment for HCV, marketed under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) since 2017 for the treatment of chronic HCV. MAVYRET®/MAVIRET® were also approved as the first and only treatments for acute HCV infection in the United States and the European Union in June 2025 and June 2026, respectively, as well as in several other countries including Canada and Australia. Enanta's active development programs in virology are focused on respiratory syncytial virus (RSV), the most common cause of bronchiolitis and pneumonia and a leading cause of U.S. hospitalization in young children and a significant cause of respiratory illness in older adults. Populations at high risk for severe RSV infection include infants and young children, adults older than 65 years of age, and those with comorbidities such as chronic heart or lung disease, diabetes, kidney disease, immunodeficiency and others. Estimates from the United States Centers for Disease Control and Prevention (CDC) for the 2024-2025 RSV season indicate that RSV led to up to 6.8 million outpatient visits, approximately 370,000 hospitalizations, and up to 24,000 deaths in the United States. Enanta estimates a global market opportunity of between $2.5 billion and $3.5 billion for an oral RSV antiviral for children and all high-risk adults, with a potential total addressable population of up to 4 million patients in the United States.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ENTA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ENTA spans 10-K, 8-K, 10-Q, 424B5.

Recent high-impact activity:

  • Enanta 10-K: $68.2M FY26 Loss, $194.5M Cash Funds Operations Into Fiscal 2029
  • Enanta Posts $23.7M Q4 Loss, Cuts Workforce by a Third, Cash Through Fiscal 2029
  • Enanta Posts 81-Cent Quarterly Loss as Patent Setback Clouds Pipeline
  • UPC Invalidates Enanta's '265 Patent; Paxlovid Infringement Action Unfounded
  • Enanta CEO Jay Luly to Retire by February 1, 2027; Tara Kieffer Named COO

Financial Snapshot

Fiscal year ended September 30, 2026
Revenue
$63M
Net Income
-$68.25M
Diluted EPS
-$2.35
Op. Cash Flow
-$42.56M
Free Cash Flow
-$42.77M
Operating Income
-$62.38M
Cash & Equivalents
$20.27M
Debt / Equity
0.00×
Net Margin
-108.3%
Shares Outstanding
29.14M sh
Source: 10-K · filed 2026-11-18 · accession 0001193125-26-466170

Short Interest & Short Volume

7.63 days to cover

FINRA reported short interest of 1,856,510 shares in ENTA as of the October 30, 2026 settlement, a 18.0% decrease from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 69.4% of ENTA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,856,510 shares as of October 30, 2026
Change vs prior period▼ 18.0%
Days to cover7.63 at avg daily volume of 243,263
Daily short volume (FINRA facilities)69.4% of 180,037 shares on November 20, 2026
5-day average short volume38.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ENTA, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.

1 recent capital raiseATM program

New At-The-Market Offering Established · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →
$7.62
52-week range · as of 2026-11-18 $7.62 – $17.15
Market cap
$222.19M
Volume
457.6K (1.5× avg)
3-mo avg 300.3K
Live data · 2026-11-21 18:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ENTA - Latest Insights

ENTA
Nov 18, 2026, 7:00 AM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $8.99
Real-time Price: $7.62 info
Change: -$1.37 (-15%) info
Market Cap: $222.19M info
ENTA
Nov 16, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.41
Real-time Price: $7.62 info
Change: -$2.79 (-27%) info
Market Cap: $222.19M info
ENTA
Nov 16, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.66
Real-time Price: $7.62 info
Change: -$3.04 (-29%) info
Market Cap: $222.19M info
ENTA
Oct 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.15
Real-time Price: $7.62 info
Change: -$3.53 (-32%) info
Market Cap: $222.19M info
ENTA
Oct 28, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.99
Real-time Price: $7.62 info
Change: -$4.37 (-36%) info
Market Cap: $222.19M info
ENTA
Aug 12, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $13.52
Real-time Price: $7.62 info
Change: -$5.90 (-44%) info
Market Cap: $222.19M info
ENTA
Aug 10, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $13.81
Real-time Price: $7.62 info
Change: -$6.19 (-45%) info
Market Cap: $222.19M info
ENTA
Jul 02, 2026, 5:03 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $15.11
Real-time Price: $7.62 info
Change: -$7.49 (-50%) info
Market Cap: $222.19M info
ENTA
Jul 02, 2026, 4:56 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.11
Real-time Price: $7.62 info
Change: -$7.49 (-50%) info
Market Cap: $222.19M info
ENTA
Jul 02, 2026, 4:54 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $15.11
Real-time Price: $7.62 info
Change: -$7.49 (-50%) info
Market Cap: $222.19M info
ENTA
Jun 23, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $14.06
Real-time Price: $7.62 info
Change: -$6.44 (-46%) info
Market Cap: $222.19M info
ENTA
Jun 23, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $14.06
Real-time Price: $7.62 info
Change: -$6.44 (-46%) info
Market Cap: $222.19M info
ENTA
Jun 18, 2026, 7:12 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $12.64
Real-time Price: $7.62 info
Change: -$5.02 (-40%) info
Market Cap: $222.19M info
ENTA
May 13, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.53
Real-time Price: $7.62 info
Change: -$6.91 (-48%) info
Market Cap: $222.19M info
ENTA
May 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.17
Real-time Price: $7.62 info
Change: -$7.55 (-50%) info
Market Cap: $222.19M info
ENTA
Mar 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.79
Real-time Price: $7.62 info
Change: -$6.17 (-45%) info
Market Cap: $222.19M info
ENTA
Mar 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.41
Real-time Price: $7.62 info
Change: -$5.79 (-43%) info
Market Cap: $222.19M info
ENTA
Feb 11, 2026, 4:43 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $14.25
Real-time Price: $7.62 info
Change: -$6.63 (-47%) info
Market Cap: $222.19M info
ENTA
Feb 11, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $14.20
Real-time Price: $7.62 info
Change: -$6.58 (-46%) info
Market Cap: $222.19M info
ENTA
Feb 09, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.73
Real-time Price: $7.62 info
Change: -$7.11 (-48%) info
Market Cap: $222.19M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets